Skip To Main Content

Our Pipeline

Clinical Development Strategy & Execution

We are developing a pipeline of allogeneic cell therapies using the lymph node as an in vivo bioreactor to grow functioning ectopic organs.

Small Animal
Large Animal
Phase 1
Phase 2
Phase 3
FDA Approval
  • Liver
    End Stage Liver Disease
    Phase 2A
  • Thymus
    POC Completed
  • Kidneys
    End Stage Renal Disease
    POC Completed
  • Pancreas
    Type 1 Diabetes
    POC Completed
stock photo, woman in lab coat and gloves, looking in a microscope

Our lead therapy is indicated for patients with End Stage Liver Disease, while our other therapies focus on Type 1 diabetes, end stage renal disease, aging, and auto-immune diseases.